Diabetes
Drug Actos Caused Bladder Cancer and
Wrongful Death of Ohio Man
Parker Waichman LLP has filed a lawsuit
alleging that Actos (pioglitazone) caused bladder
cancer and the subsequent wrongful death of an Ohio man. Actos is a drug
used to treat Type 2 diabetes; the FDA has warned that it can increase the risk
of bladder cancer after one year of
therapy.
New York, New York (PRWEB) May 14,
2013
Parker Waichman LLP, a national law firm
dedicated to protecting the rights of victims injured by defective drugs, has
filed a lawsuit on behalf of the estate of an Ohio man who developed bladder cancer and subsequently died,
allegedly from using Actos. The suit was filed on April 2, 2013, in the U.S.
District Court for the Western District of Louisiana (Case No. 6:13-cv-0706),
where it is one of thousands of cases pending in the Actos multidistrict
litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No.
6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP,
serves on the Plaintiffs’ Steering Committee in the litigation. Takeda
Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda
Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and
Eli Lilly and Company have been named as Defendants.
According to the Complaint, the Plaintiff’s
decedent took Actos from June 2002 to February 2007, at about which time he
stopped taking the drug and had developed bladder
cancer. He died in September 2007 of the bladder cancer, which was allegedly caused by Actos. The Defendants
were allegedly aware that taking the diabetes drug could lead to an increased
risk of bladder cancer, but failed
to disclose this information to the Plaintiff, his doctor and other consumers.
The suit seeks damages for extensive pain and suffering, severe emotional
distress. Actos’ side effects greatly reduced the Decedent’s ability to enjoy
life, the suit alleges.
Actos is a Type 2 diabetes medication that
was approved by the U.S. Food and Drug Administration in 1999. In 2011, the
agency updated the label to warn that users may face an increased risk of bladder cancer after taking the drug
for only one year.
Studies have continued to suggest that Actos
can increase the risk of bladder cancer.
For instance, the May 31, 2012 issue of the British Medical Journal* found that
Actos users were twice as likely to develop bladder cancer after two years. In July 3, 2012, the Canadian
Medical Association Journal** found that patients taking the medication were 22
percent more likely to get bladder
cancer.
Parker Waichman LLP continues to offer free
legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye
injuries. If you or a loved one were diagnosed with bladder cancer after taking
Actos, please contact their office by visiting yourlawyer.com. Free case
evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Tiada ulasan:
Catat Ulasan
Nota: Hanya ahli blog ini sahaja yang boleh mencatat ulasan.